Literature DB >> 26945845

Fungal empyema thoracis in cancer patients.

Masayuki Nigo1, Macarena R Vial2, Jose M Munita3, Ying Jiang4, Jeffrey Tarrand5, Carlos A Jimenez6, Dimitrios P Kontoyiannis7.   

Abstract

OBJECTIVES: Fungal empyema thoracis (FET) is a rare life-threatening infection. We sought to describe the clinical characteristics of FET in a large academic cancer center.
METHODS: We conducted a retrospective chart review of all cancer patients who had a fungal isolate from the pleural fluid culture between 1/2005 and 8/2013.
RESULTS: A total of 106 fungal isolates were identified in 97 patients. Yeasts accounted for 62% of the isolates whereas 38% were identified as molds. The most frequent pathogens were Candida spp. (58%) and Aspergillus spp. (12%). All patients with Aspergillus and 83% with Candida met criteria for proven fungal disease. Compared to the Aspergillus group, Candida FET was associated with recent abdominal or thoracic surgical procedures (44% vs. 0%, p = 0.01). Overall, 6-week mortality was high, with no significant differences between Candida and Aspergillus (31% vs. 45%, respectively [p = 0.48]). Only 1 out of 11 patients with uncommon molds died at 6 weeks, despite only 2 of them received appropriate antifungal therapy.
CONCLUSIONS: Development of FET carries a high mortality in cancer patients. A history of a recent surgical procedure is a risk factor for FET due to Candida. Isolation of uncommon molds is likely to represent a contamination of the pleural fluid.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer; Empyema; Fungal empyema; Invasive fungal infection

Mesh:

Year:  2016        PMID: 26945845     DOI: 10.1016/j.jinf.2016.02.014

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

1.  Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.

Authors:  R Welte; P Eller; I Lorenz; M Joannidis; R Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.

Authors:  Suheyla S Senger; George R Thompson; Palash Samanta; Jillian Ahrens; Cornelius J Clancy; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835

3.  Candida glabrata Empyema Thoracis-A Post-COVID-19 Complication.

Authors:  Neeraja Swaminathan; Katherine Anderson; Joshua D Nosanchuk; Matthew J Akiyama
Journal:  J Fungi (Basel)       Date:  2022-08-30

Review 4.  Evaluation and management of pleural sepsis.

Authors:  Justin K Lui; Ehab Billatos; Frank Schembri
Journal:  Respir Med       Date:  2021-07-28       Impact factor: 4.582

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.